Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX
Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX
复制标题
DOI：
10.1093/rheumatology/keh254
复制
发表时间：
2004-09-01
期刊：
影响因子：
5.5
通讯作者：
Wunder, A
中科院分区：
文献类型：
--
作者：
Fiehn, C;Müller-Ladner, U;Wunder, A
客观的。评估新型炎症靶向药物MTX-HSA的抗关节炎作用，并研究外周血单核细胞（PBMC）是否是白蛋白介导的药物递送的潜在靶细胞。方法。胶原诱导性关节炎 (CIA) 小鼠模型用于测量 MTX、MTX-HSA 或两者组合的抗关节炎作用（每组 n = 30 至 35）。此外，通过荧光激活细胞分选术（FACS）测量了 14 名 RA 患者的 PBMC 中荧光标记白蛋白（AFLc-HSA）的摄取情况。 结果。在每周两次静脉注射 (IV) 7.5 mg/kg 的等效剂量中，MTX-HSA 显着 (P
Objective. To evaluate the anti-arthritic effects of the new inflammation-targeted drug MTX-HSA and to investigate whether peripheral blood mononuclear cells (PBMC) are potential target cells for albumin-mediated drug delivery.Methods. The murine model of collagen-induced arthritis (CIA) was used to measure the anti-arthritic effect of MTX, MTX-HSA or a combination of both (n = 30 to 35 per group). In addition, the uptake of fluorescence-labelled albumin (AFLc-HSA) in PBMC of 14 patients with RA was measured by fluorescence-activated cell sorting (FACS).Results. In equivalent doses of 7.5 mg/kg intravenously (IV) twice a week, MTX-HSA is significantly (P